Chicago -- Simvastatin, a widely used cholesterol-reducing drug, may halt the progression of Parkinson's disease, researchers in Chicago said.
In a study using mice, researchers at Chicago's Rush Medical Center found simvastatin halted the advance of biochemical, cellular and anatomical changes seen in Parkinson's, said Kalipada Pahan, a Rush professor of neurological studies.
In the brains of mice, simvastatin blocked the activity of a toxic protein called p21Ras and improved motor functions, Pahan said Thursday in the Journal of Neurosciences.
